Lisata TherapeuticsNASDAQ: LSTA

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to discuss a recent milestone for the company: the completion of patient enrollment in the pancreatic cancer cohort of its Phase 1b/2a CENDIFOX trial.   The trial is evaluating the safety and efficacy of certepetide (formerly LSTA1) in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.

Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers

Lisata Therapeutics Inc (NASDAQ:LSTA) finds itself in an extraordinary but not unusual position emblematic of the challenges faced by small-cap biotech companies over the past three years as they seek recognition in a market that has performed ‘a 180' turn since the peak of Covid vaccines interest in the sector in 2021. Risk capital has been sidelined during this politically and economically volatile period, not just in life sciences, but across microcap markets internationally.

BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June:

The FDA grants Orphan Drug designation to Lisata's (LSTA) main experimental product, LSTA1, for treating osteosarcoma, leading to an increase in the stock price.

Lisata's (LSTA) lead investigational product candidate, LSTA1, gets Rare Pediatric Disease Designation for treating osteosarcoma. Stock rises.

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET

Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.

Lisata Therapeutics Inc, a clinical-stage pharmaceutical firm specializing in innovative cancer therapies, said it has completed patient enrollment in the Phase 2b ASCEND trial for its pancreatic cancer drug candidate, LSTA1, nearly six months ahead of schedule. The ASCEND trial, a critical initiative for Lisata, involves 155 patients and compares the standard-of-care (SoC) gemcitabine and nab-paclitaxel against SoC plus LSTA1.